Jefferies Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $2.1M | Sell |
19,171
-4,252
| -18% | -$539K | 0.02% | 587 |
|
|
2022
Q2 | $3.1M | Buy |
23,423
+3,528
| +18% | +$463K | 0.03% | 487 |
|
|
2022
Q1 | $2.64M | Sell |
19,895
-4,276
| -18% | -$513K | 0.02% | 598 |
|
|
2021
Q4 | $2.82M | Sell |
24,171
-13,922
| -37% | -$1.64M | 0.02% | 668 |
|
|
2021
Q3 | $4.58M | Buy |
+38,093
| New | +$4.43M | 0.03% | 461 |
|
|
2021
Q2 | – | Sell |
-18,526
| Closed | -$2.03M | – | 1656 |
|
|
2021
Q1 | $1.84M | Sell |
18,526
-10,026
| -35% | -$1.01M | 0.02% | 716 |
|
|
2020
Q4 | $2.85M | Buy |
28,552
+1,466
| +5% | +$155K | 0.02% | 597 |
|
|
2020
Q3 | $2.97M | Buy |
27,086
+27,027
| +45,808% | +$3.01M | 0.03% | 433 |
|
|
2020
Q2 | $6 | Buy |
+59
| New | +$6.09K | ﹤0.01% | 1206 |
|
|
2020
Q1 | – | Sell |
-3,805
| Closed | -$379K | – | 2055 |
|
|
2019
Q4 | $379K | Buy |
3,805
+1,017
| +36% | +$95.7K | ﹤0.01% | 1972 |
|
|
2019
Q3 | $249K | Buy |
+2,788
| New | +$242K | ﹤0.01% | 2264 |
|
|
2019
Q2 | – | Sell |
-45,000
| Closed | -$3.64M | – | 2517 |
|
|
2019
Q1 | $3.64M | Buy |
45,000
+31,979
| +246% | +$2.52M | 0.03% | 572 |
|
|
2018
Q4 | $989K | Sell |
13,021
-6,147
| -32% | -$480K | 0.01% | 1161 |
|
|
2018
Q3 | $1.52M | Buy |
19,168
+16,418
| +597% | +$1.24M | 0.01% | 1107 |
|
|
2018
Q2 | $193K | Sell |
2,750
-32,418
| -92% | -$2.33M | ﹤0.01% | 2038 |
|
|
2018
Q1 | $2.46M | Sell |
35,168
-6,632
| -16% | -$459K | 0.01% | 769 |
|
|
2017
Q4 | $2.9M | Buy |
+41,800
| New | +$2.82M | 0.01% | 803 |
|
|
2017
Q3 | – | Sell |
-107,705
| Closed | -$7.34M | – | 2323 |
|
|
2017
Q2 | $7.34M | Buy |
107,705
+102,030
| +1,798% | +$6.66M | 0.05% | 364 |
|
|
2017
Q1 | $353K | Buy |
5,675
+5,557
| +4,709% | +$323K | ﹤0.01% | 1753 |
|
|
2016
Q4 | $6K | Sell |
118
-4,217
| -97% | -$239K | ﹤0.01% | 2158 |
|
|
2016
Q3 | $285K | Buy |
+4,335
| New | +$283K | ﹤0.01% | 1826 |
|
|
2016
Q2 | – | Sell |
-16,927
| Closed | -$953K | – | 2133 |
|
|
2016
Q1 | $953K | Buy |
16,927
+16,907
| +84,535% | +$1.02M | 0.01% | 1163 |
|
|
2015
Q4 | $1K | Sell |
20
-61
| -75% | -$4K | ﹤0.01% | 2225 |
|
|
2015
Q3 | $5K | Buy |
81
+61
| +305% | +$4.01K | ﹤0.01% | 2193 |
|
|
2015
Q2 | $1K | Sell |
20
-14,673
| -100% | -$1M | ﹤0.01% | 3195 |
|
|
2015
Q1 | $1M | Buy |
14,693
+2,319
| +19% | +$161K | 0.01% | 1046 |
|
|
2014
Q4 | $871K | Hold |
12,374
| – | – | 0.01% | 1041 |
|
|
2014
Q3 | $884K | Sell |
12,374
-239,802
| -95% | -$17.6M | 0.01% | 1057 |
|
|
2014
Q2 | $18.7M | Buy |
252,176
+220,795
| +704% | +$16M | 0.16% | 108 |
|
|
2014
Q1 | $2.04M | Buy |
31,381
+30,902
| +6,451% | +$2M | 0.02% | 608 |
|
|
2013
Q4 | $28K | Sell |
479
-121
| -20% | -$6.57K | ﹤0.01% | 1780 |
|
|
2013
Q3 | $31K | Sell |
600
-21,043
| -97% | -$1.06M | ﹤0.01% | 1803 |
|
|
2013
Q2 | $1.02M | Buy |
+21,643
| New | +$1.1M | 0.01% | 761 |
|
Other funds holding AZN
Jefferies Group's AZN Position: Q3 2022 in Review
Jefferies Group reduced its AstraZeneca (AZN) stake by 18% in Q3 2022, selling an estimated $539K and leaving 19,171 shares worth $2.1M. The position accounts for 0.02% of the portfolio, ranked #587.
Jefferies Group first reported a position in AZN in Q2 2013 and has held it in 33 quarters since. The position peaked at $18.7M in Q2 2014. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.
- Jefferies Group held 19,171 shares of AstraZeneca worth $2.1M as of Q3 2022.
- Jefferies Group sold 4,252 AstraZeneca shares in Q3 2022, an estimated $539K.
- AstraZeneca made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #587 holding.
- Jefferies Group first reported a position in AstraZeneca in Q2 2013 and has held it in 33 quarters since.
- Jefferies Group's AstraZeneca position peaked at $18.7M in Q2 2014.
- 965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.